Algert Global LLC purchased a new position in Teleflex Incorporated (NYSE:TFX - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 26,220 shares of the medical technology company's stock, valued at approximately $3,623,000. Algert Global LLC owned 0.06% of Teleflex at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. T. Rowe Price Investment Management Inc. grew its holdings in shares of Teleflex by 4.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,173,121 shares of the medical technology company's stock worth $1,098,693,000 after purchasing an additional 261,279 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Teleflex by 69.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 867,864 shares of the medical technology company's stock valued at $119,927,000 after buying an additional 355,720 shares during the period. Diamond Hill Capital Management Inc. grew its holdings in Teleflex by 122.8% in the 1st quarter. Diamond Hill Capital Management Inc. now owns 584,586 shares of the medical technology company's stock worth $80,784,000 after acquiring an additional 322,222 shares during the last quarter. TD Asset Management Inc increased its position in shares of Teleflex by 0.7% in the first quarter. TD Asset Management Inc now owns 490,000 shares of the medical technology company's stock valued at $67,713,000 after acquiring an additional 3,310 shares during the period. Finally, Northern Trust Corp increased its position in shares of Teleflex by 15.2% in the fourth quarter. Northern Trust Corp now owns 462,846 shares of the medical technology company's stock valued at $82,377,000 after acquiring an additional 61,219 shares during the period. Institutional investors own 95.62% of the company's stock.
Insider Buying and Selling at Teleflex
In related news, Director Andrew A. Krakauer purchased 1,000 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The shares were bought at an average price of $115.25 per share, for a total transaction of $115,250.00. Following the purchase, the director directly owned 7,192 shares of the company's stock, valued at approximately $828,878. This represents a 16.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jaewon Ryu acquired 1,500 shares of Teleflex stock in a transaction that occurred on Tuesday, August 5th. The shares were bought at an average cost of $115.00 per share, with a total value of $172,500.00. Following the transaction, the director owned 3,727 shares in the company, valued at $428,605. This represents a 67.36% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 5,500 shares of company stock valued at $633,590. 1.40% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on TFX shares. Wall Street Zen upgraded shares of Teleflex from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Wells Fargo & Company dropped their price objective on Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a report on Friday, August 1st. Truist Financial cut their price objective on Teleflex from $140.00 to $137.00 and set a "hold" rating on the stock in a research report on Monday, May 5th. Morgan Stanley decreased their target price on Teleflex from $191.00 to $173.00 and set an "overweight" rating for the company in a report on Monday, May 5th. Finally, Royal Bank Of Canada raised their price target on Teleflex from $130.00 to $135.00 and gave the stock a "sector perform" rating in a research note on Friday, August 1st. One analyst has rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Teleflex has a consensus rating of "Hold" and a consensus target price of $141.57.
Get Our Latest Report on TFX
Teleflex Trading Up 3.5%
TFX opened at $124.0840 on Wednesday. The company has a quick ratio of 1.44, a current ratio of 2.41 and a debt-to-equity ratio of 0.42. Teleflex Incorporated has a 52 week low of $108.90 and a 52 week high of $249.90. The stock has a market cap of $5.48 billion, a PE ratio of 29.20, a PEG ratio of 1.67 and a beta of 1.08. The business has a 50 day moving average of $117.85 and a 200-day moving average of $131.65.
Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.36 by $0.37. The company had revenue of $780.90 million for the quarter, compared to analysts' expectations of $771.53 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The firm's revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.42 earnings per share. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. Equities research analysts predict that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.
Teleflex Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 15th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Friday, August 15th. Teleflex's dividend payout ratio (DPR) is 32.00%.
Teleflex Profile
(
Free Report)
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.
Read More
Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Teleflex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teleflex wasn't on the list.
While Teleflex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report